Nucleotide sequence of the bovine parainfluenza 3 virus genome: the genes of the F and HN glycoproteins

Shinya Suzu, Yuko Sakai, Tatsuo Shioda and Hiroshi Shibuta*

Department of Viral Infection, Institute of Medical Science, University of Tokyo, Minato-ku, Tokyo 108, Japan

Received December 31, 1986; Revised and Accepted March 12, 1987

Accession no. Y00115

ABSTRACT

By analysing complementary DNA clones constructed from genomic RNA of bovine parainfluenza 3 virus (BPIV3), we determined the nucleotide sequence of the region containing the entire F and HN genes. Their deduced amino acid sequences showed about 80 % homologies with those of human parainfluenza 3 virus (HPIV3), about 45 % with those of Sendai virus, and about 20 % with those of SV5 and Newcastle disease virus (NDV), indicating, together with the results described in the preceding paper on the NP, P, C and M proteins of BPIV3, that BPIV3, HPIV3 and Sendai virus constitute a paramyxovirus subgroup, and that BPIV3 and HPIV3 are very closely related. The F and HN proteins of all these viruses, including SV5 and NDV, however, were shown to have protein-specific structures as well as short but well-conserved amino acid sequences, suggesting that these structures and sequences are related to the activities of these glycoproteins.

INTRODUCTION

The paramyxovirus hemagglutinin-neuraminidase (HN) and fusion (F) glycoproteins, which project as spikes from the viral envelope, are deeply concerned with the biological activities and serological characteristics of the viruses. The virions attach to receptors on the cell surface via HN protein, and penetrate into the cells by envelope-cell membrane fusion, a process which requires F protein. The release of mature virions from the infected cell surface is mediated by HN protein's neuraminidase activity (for example, 1, 2). The paramyxoviruses are classified into subgroups according to their antigenicity, which is predominantly determined by the glycoproteins. Thus there have been many studies on paramyxovirus antigenicity using monoclonal antibodies against the glycoproteins (for example, 3, 4, 5). However, the structures of the functional domains and antigenic epitopes of these glycoproteins still remain obscure, and this situation has prompted many research groups to perform sequence studies of the F and HN genes. We have been carrying out such studies on Sendai virus and bovine parainfluenza 3 virus (BPIV3), and have already reported our results on the former (6).

BPIV3, which is the causative agent of "shipping fever" of calves, shows considerable strain differences in its glycoprotein activities (7, 8, 9), and is known to have a close antigenic relationship with human parainfluenza 3 virus (HPIV3) which causes a respiratory infection of children, although these two viruses can be distinguished from each other by detailed serological examinations (4, 10, 11).

We previously showed by use of monoclonal antibodies against the viral glycoproteins that F protein of BPIV3, like other paramyxoviruses (for example, 12), consists of F1 and F2 subunits linked to each other by disulfide linkages, that the cleavage of the precursor F protein into these subunits is achieved by some cellular endoprotease, and that the HN protein of BPIV3 really does carry both hemagglutinin and neuraminidase activities (13).

In the preceding paper, we presented the nucleotide sequence of the BPIV3 genome from its 3' end to the terminal point of the membrane (M) protein gene, through the nucleocapsid (NP) protein and polymerase-associated (P) protein, as well as the non-structural "C" protein genes. Here we report the nucleotide sequence of the subsequent genome region in which the F and HN genes are located, and compare their deduced amino acid sequences with those reported for Sendai virus (6, 14, 15, 16, 17), HPIV3 (18, 19), SV5 (20, 21), Newcastle disease virus (NDV) (22, 23) and measles virus (24).

MATERIALS AND METHODS

Viruses, preparation of viral RNA, synthesis and cloning of complementary DNA (cDNA)

CDNAs of viral genome RNA were constructed and cloned from the 910N strain of BPIV3, and cDNAs of viral mRNAs from the 910N, M and SC strains of the virus (8, 9) according to the method of Okayama and Berg (25, 26) as described in the preceding paper. Bacterial colonies carrying plasmids were screened for the presence of viral cDNA inserts with the viral 50S RNA probe, and for overlapping cDNA inserts with appropriate cDNA probes, as described previously (6).

Sequence determination of cDNA

CDNAs were cleaved with appropriate restriction endonucleases into fragments and which were sequenced mainly by the dideoxy method of Sanger et al. (27) using the M13 phage system (28). In some experiments the chemical cleavage method of Maxam-Gilbert (29) was also employed.

Gene expression from cDNA

SV40 transformed CV-1 (COS-1) cells were transfected according to Wong and Hiranao (30) with plasmids containing cDNA inserts, which were primed and cloned with a pcDV1 expression vector from the viral mRNAs. The cells were stained by indirect immunofluorescent techniques using rabbit antiserum against 910N virus (31) and mouse monoclonal antibodies directed to the F and HN glycoproteins (13) of the same virus.

Enzymes and other materials

Fluorescein isothiocyanate conjugated (FITC) goat antibody against rabbit IgG was purchased from Behringwerke AG, Marburg, West Germany; FITC rabbit antibody against mouse IgG from Miles-Yeda, Israel; and others were the same as described in the preceding paper.

RESULTS

Nucleotide sequences of the F and HN genes of BPIV3 genome RNA

The nucleotide sequence of a viral genome region, following the M gene region presented in the preceding paper, was determined from cDNA clones



Fig. 1. Locations of cDNA clones (PT38 to P152) in the genome RNA and the sequencing strategy. The numbers in kilobases (Kb) under the top line show nucleotide positions from the genome 3' end. Restriction map is also presented on the top line. Arrows indicate the cDNA fragments sequenced and the direction of sequencing. Positions of the open reading frames of the 4th and 5th genes are denoted in the bottom.

Nucleic Acids Research

10	20	30	40	50	60	70	80	90	100	
3' gcguu	AAAAGGUCGG	AAGUAAUGGA	CCACUUAAAU	CUAUGAUGGG	UUUAUAGUAU	cennnncenc	AGCCCUUUUA	GUCUGUCAUU	UUGGUUGUUA	4800
GGACUGUGGG	cueueeceuc	UGGUCCGAUG	GGUGUCCUCU	UUUUAGUUUU	UGAAUCCUAG	UUUCCCUAGU	GGUGUUUGAG	GCUCGUUGUC	AAUUUGGUUG	4900
GUUAUGUAUC	UAGUGUCCUC	υυυυςυυυυς	сплппсплп	00000000000	UUUUUUGUGG	CGUUUCUGGC	UCUAGUUAGU	CUCGUGGGUG	UUGGUUCGUC	5000
UUCUUUCGGU	UCCGGGCGGU	eeenennnen	GNEENNENNE	GGACGUCUGU	nceneeccne	ACUUCUGGUU	υυςουοουςο	CGUAGUCUGU	ACUAGUAGUG	5100
UUUGUGUUAG	UAUUAGUAUG	AUUAUUAUAG	GGGUAGUAAA	ACAGUUUAUC	UGUAUUGUUU	UGAAGUUGCA	CAUCCACAUA	AUCAGUUAUU	GGGGUUUCCA	5200
UACUUCUAAA	GUGUUUUAAA	GCUUUGCUCU	AUGAAUUAUA	AUUCAAACUA	UGGGUUUUAU	CUCUUGAGUG	UGAGUACACC	CCUAGUUGUC	UAUUUGGUUA	5300
UGUUCUUUGA	UAACCUGUCU	AACUAGUAAG	GAGAUAUACU	ACCUGAUUUU	AAUGUUUUUC	UACACUAUCA	UCAUUCAGUA	CUCUGAUUGU	UAUUGUGGUU	5400
AAGAUCCUGU	UUCGCUAAAA	AGCCUCUUUA	UUAACCCUGU	UAACGCUAUC	CCUAUCGGUG	GAGUCGUGUC	UAAUGGCGUC	GUCAGCGAGA	ACAGCUCCGU	5500
υυυουςςουυ	UCAGUCUGUA	UCUCUUUGAG	UUUCUUCGAU	AUUCUCUGUG	UUUAUUCCGU	CAUGUUAGUU	AAGUUUCAAG	ACAUCCAUUA	GACUAACAAC	5600
GUCAAUUUAG	UCAAGUUCUA	AUACAGUUGU	UACUUUAACA	UGGAAGUUAG	UGUUCUAAUC	CAACACUUCG	UCGACCCGAU	UUUGAUCCUU	AACGUAAUUG	5700
GGUUGUAAUG	AGUCUUAAUU	GUUUAUAUAA	ACCACUAUUA	UAUCCCUGUG	ACUUUCUUUU	CCCCUAUUUU	AAUGUCCCCU	AUCGUAGCGA	UAUGGUGUGU	5800
UUGUAUUGUC	UUUAUAAAUG	AUGAAGUUGU	CAACUGGUUA	UACUGUAAAU	ACUAGAUAAU	AAGUGACUUA	GUUAGUUUUA	CUCUCAUUAU	CUACAACUAA	5900
ACUCACUAAU	GAGUUAGUGA	GAAGUUCAAU	CUGAAGGAAA	CAAUUGAUUU	UAUAGUUUAU	GAGUUUAAAU	AUUUCAUCUA	AGAUAUAGUA	UGUUGUAUGU	6000
nccennncnc	ACCAUAUAAG	GCGAAGGGUU	AGUGUAUUAC	uguuuuccuc	GAAAGGAUCC	ACCACGACUA	UAAUUUCUUA	CGUAUCUUCG	UAAGUCGUCA	6100
AUAUAUACAG	GAAGACUGGG	UCCGAAAUGU	GAUUUAGUGC	UCUAUCUCUU	AACAAAUAGU	CCCUUAUAUU	GUGUCACAGG	AUUCUGAUAA	CAAUGUAGUC	6200
UACAUCAUGG	UGCUAUACGU	AAACACUUAC	CACCUAAUUA	ACGUUUGACA	UAUUGUUGAU	GUACAUGUAC	AUUACCUCAA	CUGUUAUCUU	AUUUAGUUAG	6300
UGGACUAGUU	CCUUAUUUUU	AGUAUUGUGU	AUUUCUUACA	GUUCAUUAUC	CAUAUUUGCC	UUACAAUAAG	UCAUGGUUAU	cucuucccus	UAAUCGUUGA	6400
AUAUGUAAAC	UACUGUAGUA	UAAUUUAUUG	AGACAACGGG	AAUUAGGCUA	ACUAUAUAGA	UACCUUGAGU	UGUUCCGUUU	UAACCUUGAC	CUUCUUAGCU	6500
UUCUUACCUA	UUUCUUUAGU	UUAGUUUUCA	AUCUAAGACA	ACCUUCAACC	AUAGUUAGAU	CACGUUGUUA	AUGGUAUUAG	UAUCACUACU	AUCAGCAGGA	6600
UAAGUAUUAG	UUAUAUUGUU	AAUAACAUCA	GUAUUAGUCU	GUGGUAUCUU	AAGUCCCCUU	UUUAGUUUUG	CUGUUUUUAU	CACUUGGCAU	ACAUGAUUGU	6700
UCAUCUGUUA	CUCUAAUAUG	CACUAAUUUA	UAUCUUUCAU	GUUUUUUGAA	uccuuguuuc	AACGAGUUGU	GUCGUUGUGG	ucueucueeu	UUUCAGUCAC	6800
GUCUCUGCUG	UGGUUWAAGU	UUUUACCUUA	UAACCUUUGU	GUGUUUGUCG	UGUUUCCUGU	GAUUGUUACU	UGAACCCUGU	UGGUCUCUGU	cnenencenc	6900
GUUUCGGUGU	UUAUAGUAUU	ACAUGUAGNA	GACCUGUUGU	UGUAGUUGUU	AUAAUAGUCA	GUAAAAAUAU	UACUAUAACU	AUUUAAAUUA	AGUUCUCUUG	7000
UUAGUGUUGU	UUAAUUACAA	CGUCCUUUAU	UCCUUUCUUA	AGCGUCGUUA	UCUAUGGUUU	UAAGUUUUCU	GGAGUCUACU	GUAACCAUGG	AGUUAUGUUA	7100
GUCCUUAUUU	GUGUUCUGAA	GAAUGUUAAG	UCUCAGUACA	AGUUUUGAUA	UAAGGUAAUA	GUAAUUGUGU	UGUUUACAGU	CUAGAGUCUU	UUAAAUAGUU	7200
GCUAGAGUGC	UGAUUUUCUC	UUGUAGUUCU	CCAUGGUUAU	GUCUCUUACU	GAGUACUAUC	ACCAUAUCUU	GGAGAUUUAG	GCCUGUUUAA	GACCUCUACA	7300
UGUAGACCAU	UAGGUAGAAA	UUGUUCAUCA	GGGUUCUAUU	CUGAUUAUGG	UCCCGGUCCA	AAUAAUCGUU	GUAGGUGAUG	ACAUUUACCG	ACGUAAUCUG	7400
AGGGUAGAAA	UCGUUAGUUA	UUAGAUUAGA	UGCGAAUGUG	GAGAUUAGAA	UAAUGGGUCC	CGACAGUUCU	AUAUCCUUUU	AGAAUGGUUC	AUGAUGUUUA	7500
UCCCUAUUAA	UGAUAUUUAA	GUCUAAACCA	UGGACUAAAC	UUGGGUUCUC	AGUGUGUAUG	AAUUAUAAAU	CUACUGUUAU	CCUUUAGGAC	GAGGGAACGU	7600
GAUAACUUGU	GUCUACAAAU	AGUUGAUACA	AGUUGGGGUU	UUCAACUACU	CUCUAGUCUA	AUGCGUAGUU	GUCCAUAACU	CCUGUAACAU	GAACUGUAAC	7700
AGUGAUCAUU	ACCUAAUUAA	UAUUGUUGUU	CUAAGUGCUU	AUUAUUAUAU	UGAAAACUAU	UUGGAAUACG	UCGUAAUAUA	GGUAGUCAUC	CUGGUCCUUA	7800
UAUAAUAUUU	CUGUUUCAAU	AGAAGGAGCC	UAUACCUCCA	GAUCUCGUAC	uucuuuuscc	CCUGCAUUAU	ACGUUGUGUU	GACCAACAGG	ACCGUUUUGU	7900
GUCUCUCUGA	CGUUAGUCCG	GAGAAUGUCG	GGUACCAAGA	GUUUAUCCUC	UUACCAUUUA	AGGUAAUAGC	AACAACUAUU	UCCAUAUCUA	UGUUGGAAAU	8000
CGAAUUCUCA	CACCUGAUAA	GGUUACUCUG	UUUUGAUAAC	CCCCAGUCUU	CCUUCUGACG	AAAAUAAUCC	ACUGUCUUAU	AUGUAUAUAU	GAUCUAGAUG	8100
CUCAACCGUG	UCAUUUAAUG	UCAAUCCCCA	UUAACUGUAA	AGACUAAAAU	UAUUAUAUUC	UUAUUUAACC	UGAACCGUAU	UACAUGAUAG	uecceeuccc	8200
UGACUACUUA	CAGGUACCCC	AGUAAGUACG	GGUCUGCCUA	CGUAUUGUCC	UCAAAUGUGA	CUACGUAUAG	GUGAUUUGGG	UAGUCCCUCA	UAACAUAGGA	8300
GUCAGUAAGA	ACUAAGUGUU	UUUAGGUCUC	UUUUGGGUUA	GUAAUGGAUA	AGUUGUCGAU	GUUUAUCCCA	UUUACUUAAC	CGAUAUAUGU	UGUCUUGUGA	8400
AGGUCGACGU	AUGUGUUGUU	GUUUAACAUA	GUGUGUGAUA	CUAUUUCCCA	UAACAAAAGU	AUAUCAUCUU	UAUUUAGUGU	CUUCAAACUU	SUGCAAAGUU	8500
GGAUACAAUA	AAUUUUGUCU	UCAAGGCUUU	UUGACGUCGA	UUUGACUAGG	GGCGUGUGAC	UUGUAAUCUA	CUGUGUGUAU	cuuugguggu (JUGUCUGUUG	8600
UGUCCUCUAU	UACGUUCUGU	GUUUCUUUA <u>a</u>	R2	AUCCUCCUUU R1	<u>c</u> acacauguu	CUCUACCUGU	GGCUUAGGGU	GUCGCCAUGU (JGUAGACUGU	8700

Fig. 2. The RNA sequence of the BPIV3 genome (910N strain) following the 3' proximal 4705 nucleotides presented in the preceeding paper, expressed in negative sense. Enclosed sequences correspond to the open reading frames. R1 and R2 are the repeating consensus sequences.

according to the sequencing strategy illustrated in Fig. 1. The cDNA clones were constructed from genome RNA by the method of Okayama and Berg (25, 26) after in vitro polyadenylation of the RNA. The cDNA clones, PT38 and P95,



Fig. 3. Immunofluorescent monoclonal antibody staining of cDNA-transfected COS-1 cells. Left; transfected with cDNA clone M420 and positively stained with monoclonal antibody #31 against the F protein. Right; transfected with cDNA clone M176 and positively stained with monoclonal antibody H-1 against the HN protien. Two examples are presented for each.

were the same clones as those used in the preceding paper to determine the NP, P+C and M genes. Other overlapping clones were selected by colony hybridization tests using appropriate cDNA probes. The nucleotide sequence from position 4,706 to 8,700 of the genome RNA thus deduced is presented in Fig. 2.

The regions between nucleotide positions 4,855 and 6,747 and between 6,751 and 8,638 were considered to be the 4th and 5th genes, respectively, since each contained a large open reading frame (boxed in Fig. 2) flanked upstream by the starting consensus sequence R1 and downstream by the terminating consensus sequence R2.

The 4th and 5th genes were identified as the F and HN genes, respectively, by immunofluorescent monoclonal antibody staining of the gene products expressed in COS-1 cells. These cells transfected with clone M420, which was constructed from mRNAs of the M virus, and colony-hybridized with a fragment of the 4th gene cDNA of the 910N virus genome, were positively stained with monoclonal antibody #31 directed to the F protein of 910N virus (13) (Fig. 3). CDNA clone M176, constructed from M virus mRNAs, and corresponding to the 5th gene of the 910N virus, produced a protein which, upon transfection of COS-1 cells, could be stained by the monoclonal antibody H-1 directed to the HN protein of the 910N virus (31) (Fig. 3).

When compared with Sendai virus, SV5 and NDV, it was very characteristic of the BPIV3 genome for the 3' non-coding region following the R1 of the F gene to be extremely long (235 nucleotides) and highly U-rich. Although a similar feature was also observed in the F gene of HPIV3, the non-coding region of BPIV3 was 42 nucleotides longer (18).

Amino acid sequence of the F protein and its comparison with those of other paramyxoviruses

The F protein of BPIV3 910N strain, deduced from the nucleotide sequence, consisted of 540 amino acids, calculated molecular weight of the

EPIV3 HPIV3 Sendai SV5 NDV	MIIT .PT* MTAYIQRSQC.** .GTI - <u>SSTRIPIPLM*</u> .	NTIIIILIISPS IL*TTM.MA. F****.TTL V IQF***SC*LAG IR.A*A.SCVHL	FCQIDITNLQRVG KH SPRDR.SN*. AGS*.PAA.MQ*. <u>A</u> SS*.GRP.AAA.	VLVNNPKGMM 	AGSH. * **. YYTEAS*AF***K YYTSQ.GS*.*K
BPIV3 HPIV3 Sendai SV5 NDV	LIPKIENSH SC D.N .*.G**FEN G. .M.T.*SPISG. .*.NMPKDKEA.	GDQQINQYKKLL K* .TA.*IS. NITS.SS.NAT* AKAP*EA. <u>N*T</u> .	DRLIIPLYDGLKL *. N*R.A.D. T*.*Q.*G*N.ET TT.*TG.S**R	QKDVIVVSHE SNQ. .EA*.T.* <mark>N</mark> I*NQ**P* IQ*S*TT.GC	TNNNTNSRTKRFF *.EDP .TQ.AGAPQS R.R*A R.Q <u>I</u>
BPIV3 HPIV3 Sendai SV5 NDV	GEIIGTIAIGIA' .G**.*. .A**.*. .V*LA.*.*. .A**.*.	TSAQITAAVALV G*A .A*S*	EAKQAKSDIEKLK * *ERAL*. K.NENAAA.LN Q.N.NAAN.L*	EAIRDTNKAV 	QSIQSSVGNLIVA
BPIV3 HPIV3 Sendai SV5 NDV	VKSVQDYVNNEI *K. *.**FD .QAH*.SV* .GKM.QFDQF	VPSITRLGCEAA A K.A.*ET. S.AAAN.K.Q NN + AQE.D.IKI	GLKLGIALTQHYS QK A.*K DAI*.SI.NLYL* TQQ*.*E.NLYL*	ELTNIFGDN1 LTAS.F THNQ. T*PQ.	GTLKEKGIKLQGI .*.0 .*GS*TA* TNPALSP.T*.A* T*PALTO*T*.A*
BPIV3 HPIV3 Sendai SV5 NDV	ASLYHT <mark>NITE</mark> IF ⁷ R SSA RI.LG*T*PT*VI YN.AGG.MDY*L	ITSTVDQYDIYD K IRTG. SN.S . EK.FNT.ISAA* .KLG.GNNQ*SS	LLFTESIKMRVID V **YQGT S*GL*TGQ**G .*G*GL.TGNP.L	VDLSDYSITI NA ER.M* **YMQMV* Y.SQTQL*G*	QVRLPLLTKISNT **L S.**.*.*E*PGV K*ETVΩPA. TS*GN*N.M
BPIV3 HPIV3 Sendai SV5 NDV	QIYKVDSISYNI * L.H.ASI ID*A*AF.I RATY****.VST	QGKEWYIPLPNH .N*S. D.E*T*.S. NNQ.VMAQTR FKGFASAL*.KV	IMTKGAFLGGADI * .L**AS* *.VT.SL*QAYPA *TQV.SV*EEL.T	KECIEAFSSY T*.*.SRL*. SQ.TITPN*V YSTDLDI	ICPSDPGFTLNHE
BPIV3 HPIV3 • Sendai SV5 NDV	IENCLSGNITQCI M.S	PKTIVTSDVVPR .*.*.K* .V.K.VDS**.* IF*P.VGSF*T. MY*KTEGA*TTP	YAFVNGGLIANCI *** F** FVLFD.I*YR .MT*K <u>.S*</u> K	TTTCTCNGVE 	NRI <mark>NQS</mark> PDOGIKI RP.S.DRSK.*VF AV.L.PSSSP*T* GI.S.NYGEA*S*
BPIV3 HPIV3 Sendai SV5 NDV	ITHKECQVIGING NT *DN.G**. .DMYK.VS*Q*DI .DRHS.N.*S*D	GMLFSTNREGTL N* .VELYAR.HD NLR.*ITQLA <mark>N*</mark> .ITLRLSG.FDA	ATYTFDDIILNNS .FPNT .WGVQN*T GPA TYN*TIK*ESSQI TYQKNIS.*DSQV	VALNPIDISM DI *.*R.*I *S*D.*Q *VTGN <u>*</u> I	LELNKAKLELEESK
BPIV3 HPIV3 Sendai SV5 NDV	EWIKKSNQKLDS ** AE*E.ARKI.SE QH*AQ.DTY.SA *K*EE.SK	VGSWYQSSATIT *.N.HTI RN.RE.*I *T.ATT*.VLSI .NVKLT.*SA <u>*I</u>	IIIVMIVVLFIIN .***** TVM*L**I .A.CLGS*GL.*I TY.ALTA*SL*CG	ITIIVVIIR ***A**Y .V*.*Y.I .L*S*W*I .LS*.*ACYI	HRIQGKNQNDKNS YK*.RV.Q.D R.SMLMGNP.DRI LT.VVA.R.RMEN MYK.KAQ.KTLLW
BPIV3 HPIV3 Sendai SV5 NDV	EPYVLTSRQ KN* PRDTY.LEPKIRI FV.HK LGNNTLGQMRAT'	HMYTNGGFDAMA IKM	(540) (539) EKR (565) (529) (553)		
BPIN	3 F PROTEIN	N MOLECULA	R WEIGHT = 60	006	
ALA= CYS= HIS= MET= THR=	=24 4.44% =11 2.04% = 9 1.67% = 7 1.30% =42 7.78%	ASN=39 7.2 GLN=27 5.0 ILE=79 14.6 PHE=14 2.5 TRP= 3 .5	ASP=26 0% GLU=26 3% LEU=45 9% PRO=15 6% TYR=17	4.81% 4.81% 8.33% 2.78% 3.15%	ARG=15 2.78% GLY=30 5.56% LYS=36 6.67% SER=41 7.59% VAL=34 6.30%

Fig. 4. Comparison of the deduced amino acid sequence of the F protein of BPIV3 with those of HPIV3, Sendai virus, SV5 and NDV, and the deduced amino acid composition of BPIV3 F protein. Underlines and dashed underlines indicate hydrophobic regions and regions well conserved by all viruses, respectively. Enclosed sequences are the putative carbohydrate attachment sites. Arrow indicates the putative cleavage site. (.); amino acid identical with that of BPIV3. (*); amino acid of similar nature to that of BPIV3 (R and K, S and T, D and E, and, I, L and V).

VIIC		proceins	becween virus	cə.
			Prot	ein
Combi	ina	tion	F	HN
BPIV3	-	HPIV3	80	77
BPIV3	-	Sendai	44	47
BPIV3	-	SV5	23	21
BPIV3	-	NDV	22	21
BPIV3	-	Measles		< 10
Sendai	-	SV5	24	22
Sendai	-	NDV	22	23
Sendai	-	Measles		<10
sv5	-	NDV	32	32
sv5	-	Measles		<10
NDV	-	Measles		<10

Table 1. Amino acid homologies (%) of viral proteins between viruses.

non-glycosylated form and estimated one of the glycosylated form being 60K and 75K (31), respectively. Its amino acid sequence, together with those for the F proteins of Sendai virus (6, 14, 15), HPIV3 (18), SV5 (20) and NDV (23) are presented in Fig. 4, where the amino acid sequences are aligned by insertion of minimal gaps to illustrate the maximum homology between the viruses. The deduced amino acid composition of the F gene product of BPIV3 is also presented in Fig. 4.

Comparison of the sequences showed that 80 % of amino acids were conserved between BPIV3 and HPIV3, and that the former was only one amino acid residue longer than the latter. The most different region was located near the carboxyl terminal. In contrast, the overall homologies between BPIV3 and Sendai virus, between BPIV3 and SV5, and between BPIV3 and NDV are 44 %, 23 % and 22 %, respectively (Table 1). However, all these F proteins shared common structural characteristics. In all the most hydrophobic region was near the carboxyl terminal (underlined in Fig. 4), which is thought to act as the anchor in the viral envelope (6, 14, 15, 18, 20, 23). Another hydrophobic sequence, which was detected at the amino terminal of the F1 proteins of Sendai virus, SV5 and other paramyxoviruses, and is thought to act as a functional domain during membrane fusion (32, 33), was also well conserved in BPIV3 and HPIV3 (underlined in Fig. 4), strongly suggesting that the Arg residue, which was immediately followed by this sequence and preceded by Lys, was also the cleavage site (indicated by arrow in Fig. 4) for the BPIV3 F protein. This basic amino acid layout was identical to that of the cleavage site of the HPIV3 F protein (18). Another common hydrophobic region, located right at the amino terminal end, and ending in Cys followed by Gln (also underlined in Fig. 4), was most probably, based on evidence from Sendai virus (14), the signal peptide.

Moreover, not only 10 Cys residues but also 7 Gly and 4 Pro residues were completely conserved at corresponding positions in these five viruses. These amino acids are important in determination of tertiary structure of proteins, since Cys forms intramolecular disulfide linkages, and both Gly and Pro promote turns in the secondary structure (34).

In addition, four short but well-conserved regions were noted in all the F proteins (dashed underlines in Fig. 4).

As to the presumed Asn-linked carbohydrate attachment sites, which are also indicated in Fig. 4 (the carbohydrate signal sequences in the anchoring domain were neglected), there was considerable variation, and none was conserved among these five viruses, although one site was shared by BPIV3, HPIV3 and Sendai virus, and another by BPIV3, HPIV3, SV5 and NDV. Even between the closely related BPIV3 and HPIV3, each had two and one unique sites, respectively, although they shared three common sites.

Amino acid sequence of the HN protein and its comparison with those of other paramyxoviruses

The HN protein of BPIV3 consisted of 572 amino acid residues. Its molecular weight deduced for the non-glycosylated form was 65K while that estimated for the glycosylated form was 76K (13). The deduced amino acid sequence of the HN protein of BPIV3, as well as those reported for Sendai virus Z strain (6), HPIV3 (19), SV5 (21) and NDV (22) are presented in Fig. 5 in the same manner as employed for alignment of the F proteins. The deduced amino acid composition of the BPIV3 HN protein is also presented in Fig. 5. The HN proteins of BPIV3 and HPIV3 had identical numbers of amino acid residues, and BPIV3 showed 77 %, 47 %, 21 % and 21 % homology with HPIV3, Sendai virus, SV5 and NDV, respectively (Table 1). A region of about 100 amino acids proximal to the amino terminal showed the most difference between BPIV3 and HPIV3, a tendency which was much more obvious between BPIV3 and Sendai virus, SV5 or NDV.

Similarly, as with the F proteins, the HN proteins of these five viruses shared common structural features, despite the variation in amino acid homology among the viruses. The most hydrophobic region in all the viruses was located near the amino terminal (underlined in Fig. 5), which is

	3	MEYW	KHTN	STKI	DTNNE	LGT	TRE	RH	SSK	ATN:	IIM	ΥI	FWI	ТΤ	ST	ILS	5 V I	FIN	IL	INL	ΙQΕ	NN
HPIV	3			HG.	AG	.Е.	* M #	АΤ.	GN.	[I	к.т	۰.	L.,	II	LV	*	. * *	1	۰.	s	ĸs	ΕK
Send	ai	.*GD	*GKR	D*YV	*TSF	's.*	. T P	(PA	.GW	ERSS	5 K A	DT	WLI	ΙL	. F	TQ	* A %	s.A	т*	.IC	. 1 1	SA
SV5						MV	AE.	AP'	VRA	CR	* * F	RT	TTI	. I F	LC	т.1	LA*	s.s		YES	тт	QК
NDV						м	D.#	AV S	QVA	.E.I	DER	ΕA	κn.	WR	LI	FR	IA.	L * L	т*	*т./	٩TS	VA
																						-
BPIV	3	HNKL	MLQE	IRKE	FAAI	DTK	IQN	TS	DDI	GTS	IQS	GΙ	NTF	RLL	T I	ួទ៖	٩VQ	NYI	ΡL	SLTÇ	0,0 M	SD
HPIV	3	AHES	L*	* N N .	.ME*	TE.	· · ^	1A .	. N . I	IDL.	• • •	• *	• • •	• •	••		• • •	• • •	• *		• •	••
Sena	a 1	RQGY	SMK.	YSMI	IVE.*	NMS	SRE	EVK	*S*'	Γ*L	RQ	E *	IA.	A *	Ν.		5	TG.	• *	L.NI	(NS	R.
575		QIMS	QAGS	TGSN	ISGLG	SIT	DLL	.NN	ILS	ANG	211	YN	SAV	Α.	P*	. LC	DTL	EST	L.	* A		
NDV		SLVY	SMGA	STPS	SDLVG	IPT	RIS	RA	• • K	/	ALG	SN	QDV	* D	R.	ΥKÇ	2.A	LES	•••	A.L!	ITE	*т
BDTV	3			***	FUOF										~							
HPTV	ž	LIKKI	C # #	1167	1 * N	UP I	QRP 1	11	HD	, ,	, ,	NP		WR	CT	SGR	122	LTS	5 P	KIRI	.1 P	GP
Send	ai	* TOM	 	· · · ·		UCF				,	· · ·	÷		•••	• •				<u>.</u>		- m -	• •
SV5		1.511	. KS		KLEC	NCG			п. А I I Т N I		ч /тм	ст.	пэ. NO	· · ·	. P	V . E		÷	с. С	E.S.		
NDV		* M N A	. TS .	* YOI	NGAA	NNG	GWG					10	цоў. Е	1 F 1 T	21	DAG		╧	v .	сл т	- N.	м. цт
				• * •			0		••••			10	• •		•0	DAL		• •	• • •	54 1	Ϋ́́	
BPIV	3	GLLA	TSTT	VNGC	IRLP	SLA	INN	IL T	YAY	SNI	тт	06	cor	IG	ĸs	Y 01	11.0	TGT	τт	TNSF	ъv	ΡD
HPIV	3		MP	. D	*.т.	v						Ř.								*		
Senda	ai	ss	G	*s	*	s	. GE	CA.	'				. A .					* . Y		*	MF	
SV5		SF*P	. A	PE	т. * .	.FS	* T K	тни	NC.	н.	. L	N.		нv	s.	N . F	*s	м	. E	PT.4	GF	. F
NDV		NF*P	AP	GS.	т. * .	.FD	MSA	тн	.c.	н.•	'.L	s.	. R .	НS	н.	н.ч	. A	*.*	* R	TTAT	GR	IF
						-			-													
BPIV	3	LNPR	VТНТ	FNIC	DNRK	scs	LAL	LN	DV	QLO	ST	PK	VDE	RS	DY	AST	GI	EDI	VL	רעוס	SN	GL
HPIV	3		**	N								• •				*	۰			N	HD	.s
Senda	ai	v	. *	YD.N			* V A	TG	RG		. м	.т		. *		s.c	»	*		.**c	LK	. R
SV5		FRTL	K.LY	LSDG	v		* S T	* P (GCI	IMY.	F۷	ST	QΡ.	. D		SF	AA	PPE	QR	1.*Þ	ΥY	ND
NDV		FSTL	R*I*	LDDI	' <u>Q</u>	<u></u>	*SA	TPI	LGCI	м	. к	VT	ЕТ.	ΕE		N . A	VP'	TLM	AH	G R * 0	FD	
					-																	
BPIV	3	IITT	RFTN	NNIT	FDKP	YAA	LYP	svo	GPG	YYP	DK	VI	FLG	YG	G					LEF	EE	NG
HPIV	3	.s	K.	· <u>· · · *</u>	Q.	•••	• • •	•••	• • • •	• • •	•••	۰.		۰.	•						ΡI	. Е
Senda	a 1		.YR.	SE*C	с.н.	FS.	• • •	•••	. N	ATE	GS	۰.		••	•					. TI	PL	ç.
575		IJ.VE		PPGV	'L. V	W.T	. N .	GT	.s.'	· I	G₩	• *	. P I	••	۰۷	IKG	TS	LWN	NQ	ANKY	FI	ΡQ
NDV		QYHE	DLD	VTTL	•• * D	WV.	N	G .	. G . S	FIC)G *	. W	.sv	•••	•					. K F	NS	PS
														_								
BPIV	3	DVIG	NTTG	C PG	KTOR	DCN	QAS					YS	PWF	SN	RR	MVN	ISI	IVV	DK	GIDI	TF	SL
HPIV.	3	NA	÷.	• ••		<u>.</u>	<u></u>					н.	<u></u>	. D	::		• •	• • •	••	.*N*	IP	к.
cvr		. TK.	K.Q.		V D	т	L.L	:				K I '	T.L	GG	*Q	v.s	SV.	۰Ω.	ND	Y*SE	RP	к*
345				м Ои		NAK	<u> </u>					•••	5	G.	. M	105	5G .			D/) I	- N	EC
NDV		T * O	FCKY		* VALD	T D	DEO	nv/			· ~ v	v n.	~ -	~~	*	100		- AC	F 61			
NDV		.т*о	EGKŸ	VIŸK	* YND	Т. Р	DEQ	DYG	QIRM	IAKS	SY	KP	GR.	GG	۰.	IQC	2 Α .	*S*	KV:	STSI	GE	DP
NDV	3	. T*Q	EGKY	VIŸK	* YND	Т . Р	DEQ			1AKS	55¥	КР(600-	GR.	GG	* .		2A .	*S*	KV:	STSI	GE	DP
NDV BPIV: HPIV:	3	. T*Q	EGKY IPMR	VIŸK QNYW	GSEG	T.P RLL	DEQ LLG	DY DR:		TRS	55¥ 575	КР(WH:	GR. S	GG KL	*. QL	IQC GVI)A.	*S* SDF			GE	DP
NDV BPIV HPIV Senda	3 3 a i	. T*Q	EGKY IPMR .S	V I ŸK QNYW	GSEG	T. P RLL	DEQ LLG	DY DR DR		TRS	5 Y 5 T S 	КР(WH:	GR. S	GG KL 	QL	100 GV1	0A.	* S * S D F * . Y	KV: NN SD	STSI IRI R 	GE	DP
NDV BPIV HPIV Senda SV5	3 3 a i	.T*Q RVWT * T. L.LP	EGKY IPMR .S .IT FSND	V I ŸK QNYW L .VLM	GSEG	T. P RLL 	DEQ LLG 	DY DR N*		TRS	SY STS • G	КР(WH: 	G R . S РМТ	GG KL Q.	*. QL 	1 Q (G V I . * .	DI:	* S * SDF * . Y	KV: NN SD HP	STSI	GEI	
NDV BPIV: HPIV: Senda SV5 NDV	3 3 a i	.T*Q RVWT * L.LP V*TV	EGKY IPMR .S IT FSND P.NT	VIŸK QNYW VLM VTLM	GSEG	T. P RLL Y	DEQ LLG K MY.	DY(DR: N*	UYIY	TRS	SY 5TS *G N.	KP(WH: .W: YF	GR. S PMT	GG KL Q. M.	*. QL YK	IQ(GVI •*• ••*•)A. (DI: 	* S * SDF * . Y	KV: NN SD HP	STSI IRI • K • T	GEI	DP
NDV BPIV: HPIV: Senda SV5 NDV	3 3 a i	.T*Q RVWT * .T. L.LP V*TV	EGKY IPMR .S .IT FSND P.NT	VIYK QNYW VLM VTLM	GSEG	T.P RLL Y	DEQ LLG K MY. T*.	DY DR N* .S' TSI	QIRN LYIY 	TRS Q Q	SY 5TS • G N. 5*.	КР	GR. S PMT	GG KL Q. M. PA	*. QL YK L.	IQC GVI * VT. YPM	DI: TF	*S* SDF *.Y *NG	NN SD HP OP	STSI IRIN • T. SA.S TATI	GE WT	DP
NDV BPIV: HPIV: Senda SV5 NDV BPIV:	3 3 a i 3	.T*Q RVWT * .T. L.LP V*TV	EGKY IPMR .S IT FSND P.NT LS	VIYK QNYW L .vlm VTLM RPGN	GSEG	T.P RLL WGH	DEQ LLG K MY. T*.	DR DR N* .S TSI	QIRM LYIY *.Y HF*.	TRS Q Q Q Q Q	SY 5TS *G N. 5*.	КР	GR. S PMT	GG KL Q. M. PA	*. QL YK L.	100 GVI •*• • • • • •	DI: TF	*S* SDF *.Y *NG		STSI IRI *T. SA.S TATI	GE WT	DP NV
NDV BPIV: HPIV: Senda SV5 NDV BPIV: HPIV:	3 3 a i 3 3	.T*Q RVWT * L.LP V*TV WHNV	EGKY IPMR .S IT FSND P.NT LS	VIYK QNYW L .VLM VTLM RPGN	S * YND GSEG 	T. P RLL WGH	DEQ LLG K MY T*. SCP	DY DR N* .S' TSI	QIRM LYIY + Y HF*	1AKS TRS Q Q.C	SY TS *G N. *C	КР	GR. S PMT L	GG KL Q. M. PA	*. QL YK L.	IQC GVI • * • • • • • • • • • • • • •	DI: TF	*S* SDF *.Y *NG GSI	NN SD HP QP:	STSI IRI *T. SA.S TATI SVI	GE WT	DP NV L
NDV BPIV: Senda SV5 NDV BPIV: BPIV: Senda	3 3 3 3 3 3 3	.T*Q RVWT * .T. L.LP V*TV WHNV P.EA	EGKY IPMR .S .IT FSND P.NT LS 	VIYK QNYW L .VLM VTLM RPGN	IGSEG 	T.P RLL WGH 	DEQ LLG K T*. SCP	DY DR N* .S' TSI	QIRM LYIY *.Y HF* CITC	TRS 2 2 2 2	SY 5TS *G N. 5*.	КР WH .W YF 	GR. S • • • • •	GG KL Q. M. PA	*. ol YK L.	IQC GVI .*. VT. YPM 	DA.	*S* SDF *.Y *NG GSI	NN SD HP OP K	STSI IRI *T. SA.S TATI SVI *.T	GEI IWT	DP NV L
NDV BPIV: Senda SV5 NDV BPIV: Senda SV5	3 3 3 3 3 3 3	.T*Q RVWT * .T. L.LP V*TV WHNV P.EA PTQQ	EGKY IPMR .S FSND P.NT LS *P	VIYK QNYW L .VLM VTLM RPGN T	IGSEG 	T. P RLL WGH ATN	DEQ LLG MY. T*. SCP R	DY DR N* .S TS DG KE GF		TRS 2 2 2 2	SY 5TS *G N. *CA	KP(WH: .W: YF YP: WL	GR. S PMT L TN	GG KL Q. M. PA	*. QL YK L.	IQC GVI ·*·· VT. YPM ··· STF	DA. DI: TF TF IPS .D.	* S * S D F * . Y * N G G S I A A N	KV: NN SD HP QP .K VS: .A	STSI IRI *T. SA.S TATI SVI GSY	GE MT AQ	DP NV L
NDV BPIV: Senda SV5 NDV BPIV: Senda SV5 NDV	3 3 a i 3 3 a i	.T*Q RVWT * L.LP V*TV WHNV P.EA PTQQ PYTF	EGKY IPMR S FSND P.NT LS P NAFT	VIYK QNYW L .VLM VTLM RPGN T	GSEG .A I.A I.A I.A I.C.P. N KN G*.S IP.Q	T. P RLL WGH ATN ASA	DEQ LLG MY. T*. SCP R	DY DR N* .S TS DG KE GF NS		1AKS 7TRS 0.0 0.0 0.0	SSY STS *G N. *G N. *C	KP(WH: YF YF WL	GR. S PMT L TN	GG KL Q. PA	*. QL YK L.	IQC GVI • * • • • • • • • • • • • • • • • • • •	DA. DI TF TF IPS S.D. CG.	SDF SDF NG SSI SSI	KV: NN SD HP ΩP: K VS: .A FIL	STSI IRI STSI SA.S TATI SVI GSY RG*F	GE	DP NV L
NDV BPIV: Senda SV5 NDV BPIV: Senda SV5 NDV	3 3 3 3 3 a i	.T*Q RVWT * L.LP V*TV WHNV P.EA PTQQ PYTF	EGKY IPMR S FSND P.NT LS *P	VIYK QNYW L .VLM VTLM RPGN 	GSEG 	T. P RLL WGH ATN ASA	DEQ LLG K MY. T*. SCP R	DY(DR: N* .S' TSI PDG(KE GF		1AKS TRS Q Q.Ο VΥ1 	SSY 5TS *G N. 5*. *DA	KP(WH: YF YF: WL	GR. S - PMT - L - TN	GG KL Q. M. PA	*. QL YK L.	IQC GVI .** VT. YPM STFF I	DA. TF TF IPS S.D. FG.I	* S * S D F * N G	KV: NN SD HP K VS: A F	STSI STSI *T. SA.S TATI SVI GSY RG*F	GT	DP
NDV BPIV: HPIV: Senda SV5 NDV BPIV: Senda SV5 NDV BPIV: BPIV:	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	.T*Q RVWT * L.LP V*TV WHNV P.EA PTQQ PYTF	EGKY IPMR S.S. FSND P.NT LS SREN	VIYK QNYW L .VLM VTLM RPGN PIIT	GSEG 	T.P RLL Y Y Y WGH ATN ASA TNR	DEQ LLG T* SCP K R R VNE	DY(DR: N* .S' TSI DGC KE GF .NS		1 A K S T R S Q · · · Q · · · · · Q · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·	SY 5TS *G N. 5*. 7DA 	KP(WH: YF YF: WL YT	GR. S PMT L TN	GG KL Q. M. PA	*. QL YK L. ST	100 GVI • • • • • • • • • • • • • • • • • • •	(DI) (DI) (TF) (TF) (T*) (T*) (T*) (T*) (T*) (T*)	*S* SDF *NG GSI GSI AAN EAT		STSI IRI *T. SA.S TATI SVI SVI CSY RG*F FHIV	GTI	DP NV L M.
NDV BPIV: HPIV: Senda SV5 NDV BPIV: Senda SV5 NDV BPIV: HPIV:	3 3 3 3 3 3 3 3 3 3 3	.T*Q RVWT * L.LP V*TV WHNV P.EA PTQQ PYTF DSQK:	EGKY IPMR S.S. FSND P.NT LS SREN SREN	VIYK QNYW L .VLM VTLM RPGN S PIIT	* YND GSEG 	T.P RLL WGH ATN ASA TNR .E.	DEQ LLG MY. T*. SCP R R VNE	DY(DR: N* .S' TSI PDG(KE GF NS	21R 1919 *	1AKS TRS Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Δ Q Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ	SY 5TS *G N. 5*. 7DA 7DA 7DA	KP(WH: YF YF WL 	GR. S PMT TN S	GG KL Q. M. PA	*. QL YK L. ST	IQC GVI •*•• VT. YPM SSTF I THY	(DI: 	* S * S D F * . Y * NG G S I A A N E A T R NH G	KV: NNNSD HP KV: KV: KV: KV: KV: KV: KV: KV: KV: KV:	STSI IRI *T. SA.S TATI SVI SVI RG*F FHIV	GTI	DP NV L M.
NDV BPIV: Senda SV5 NDV BPIV: Senda SV5 NDV BPIV: HPIV: Senda	3 3 3 3 3 3 3 3 3 3	.T*Q RVWT * L.LP V*TV WHNV P.EA PTQQ PYTF DSQK YANT	EGKY IPMR SS FSND P.NT LS P.NT LS SREN SREN V.	VIYK QNYW L .VLM VTLM RPGN PIIT 	* YND GSEG 	T. P RLL WGH 	LLG MY SCP K R VNE	DY(DR: N* .S' TSI DG(KE GF NS :LA : I.R	21 RI 1 Y I Y + . Y HF + C I T C . + . + . + . + . + . + . + . + . + . +	1AKS TRS Ω Ω Ω Ω Ω Ω Ω Ω.	SSY STS *G N. S*. DA P AAA S.G	KP(WH: YF YP: WL YT	GR. S PMT TTN S S	GG KL Q. PA	*. QL YK L. ST I 	100 GVI **** YPM N SSTFF I THY	2) A . 1 D I : 	* S * S D F * . Y		STSI IRI SA.9 SA.9 TATI SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI 	GEI	L
NDV BPIV: Senda SV5 NDV BPIV: Senda SV5 NDV BPIV: HPIV: Senda SV5	3 3 3 3 3 3 3 3 3 3	.T*Q RVWT * L.LP V*TV WHNV P.EA PTQQ PYTF DSQK YANT N*AT	EGKY IPMR .S FSND P.NT LS FP NAFT SREN 2.I.	VIYK QNYW L .VLM VTLM VTLM PIIT 	YND GSEG I.A I.A I.A I.DECP N KN G*.S IS INT I.A.N	T. P RLL 	LLG MY SCP K R VNE * *	DY(DR: N* SS TSI DGC KE GF NS :LA : LA	UTTO	1 A K S 7 T R S 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	SSY 5TS *G N. 5*. 7DA P AA 5.G	KP(WH: YF YF WL 	GR. S. . PMT 	GG KL Q. PA PS	*. QL YK L. ST I F	IQC GVI * VT. YPM SSTF I THY F RDT	DA. IDI: TF IPS IPS CG. IFY ICK ICK ICK ICK ICK ICK ICK ICK	* S * S D F * . Y * NG G S I . G S I . G S I . A A N E A T R NH	NNN SD HP K K VS A F F L I YCI	SVI SVI SVI SVI SVI SVI SVI SVI	GT	L
NDV BPIV: Senda SV5 NDV BPIV: Senda SV5 NDV BPIV: Senda SV5 NDV	3 3 3 3 3 3 3 3 3 3	.T*Q RVWT * L.LP V*TV: WHNV P.EA PTQQ PYTF DSQK: YANT N*AT EQ	EGKY IPMR.S FSND P.NT LS *P NAFT SREN Q.I. A.L.	V IYK QNYW L .VLM VTLM RPGN S PIIT S PIIT S	YND IGSEG I.A I.A I.A I.DECP N KN G*.S I.P.Q I.P.Q I.NT I.A.N I.A.N VFDS	T. P RLL WGH WGH 	LLG MY T* SCP K R VNE SSI SSI	DY(DR N* TSI DGC KE GF NS LA QQI TR	21R LYIY + Y HF CITC CITC CITC CITC CITC CITC CITC CIT	14 K S 7 T R S 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	SSY 5TS *G N. 5*. 7DA P AAA 5.G 2	KP(WH: YF YF WL YT' 	GR. S. . PMT TN 	GG KL Q. PA PS	*. QL. YK ST I F*	IQC GVI •••• VT. YPM N SSTF I THY •••F RDI VKI	IDI: TF IPS CG. IFY ICK CG.	*S* SDF *NG *NG GSI AAA EATH G. YMV	NN SD HP KV SD HP VS 	STSI IRIN SSA SSA SSY RG *F FHIV 	GEI	
NDV BPIV: Senda SV5 NDV BPIV: Senda SV5 NDV BPIV: Senda SV5 NDV	3 3 3 3 3 3 3 3 3 3 3 3	.T*Q RVWT * L.LP V*TV WHNV P.EA PTQQ PYTFI DSQK: YA <u>NT</u> N*AT	EGKY IPMR S FSND P.NT LS NAFT SREN Q.I. A.L.	VIYK QNYW L .VLM VTLM VTLM VTLM VTLM I S PIIT S PIIT S	* YND GSEG I.A IDECP N KN G*.S IP.Q YSTA S I.I.N TIANN VFDS	T. P RLL 	DEQ LLG K MY. T*. SCP K RR SSI	DY(DR N* TSI DGC KE GF NS LA QQI TR	21R1 1411 *	TRS Q Q Q Q Q Q Q Q.	SY 5TS *G N. *G N. * * CDA P AAA S *	KP(WH: YF YF YT 	GR. S. PMT L. TNN S.	GG KL Q. M. PA PS	*. QL. YK ST I. FK*	IQC GVI **. YPM N SSTF I THY F RDI VKI	IDI: TF IPS: CG. IFY IGS: N.	*S* SDF *NG SSI AAN EAT S VMV	KV: SD HP KV: SD HP K VS: A F F L I YC:	STSI IRIN SSA SSA SSY RG*F FHIV	GEI	
NDV BPIV: Senda SV5 NDV BPIV: BPIV: Senda SV5 NDV BPIV: Senda SV5 NDV BPIV: BPIV: BPIV: BPIV:	3 3 3 3 3 3 3 3 3 3 3 3 3 3	.T*Q RVWT * L.LP V*TV WHNV P.EA PTQQ PYTF DSQK YANT N*AT EQ. RSLN	EGKY IPMR.S FSND P.NT LS *P NAFT SREN .V. J.V. 2.I. A.L.	V IYK QNYW L .VLM VTLM RPGN 	YND GSEG IAA IDECP N KN GF.S GF.S GF.S GF.S GF.S GF.S GF.S GF.S	T.P. RLL WGH 	DEQ LLG K.Y. MYY. T*. SCP K KR. SRI	DY(DR N* TSI DGC KE GF NS LA QQI TR	21R LYIY + Y HF + CITC CITC - KDV FGSS +SSS	IAKS TRS Q. Q. Q. G. C. C. C. C. C. C. C. C. C. C. C. C. C.	SY TS *G N. *G N. *G N. *G N. *G N. *G *G *G *G *G *G *G *G *G *G	KP(WH: YF YF WL YT 	GR. S. . PMT L TN TTNS S	GG KL Q. M PA PS	*. QL. YKL. ST I. FK*	IQC GVI **. YPM N STF I THY F RDI VKI	IDI: TF IT* IPS G. IFY ICK CG. IFY ICK IFY	*S* SDFF *.Y *NG SSI SSI AAAN EAT S VMV	VS: . A FTU	STSI IRIN *T. SA.S TATI SVI * SCI SCI SCI SCI SCI SCI SCI SCI	GEI	
NDV BPIV: HPIV: Senda SV5 NDV BPIV: HPIV: Senda SV5 NDV BPIV: HPIV: Senda SV5 NDV BPIV: HPIV: Senda	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	.T*Q RVWT * .TL LLP V*TV: WHNV P.EA PTQQ PYTF DSQK: YA <u>NT</u> N*AT EQ RSLN *	EGKY IPMR.S FSND P.NT LS *P NAFT SREN .V. Q.I. A.L. IFQP	V I Y K QN YW L .VLM VTLM VTLM RPGN S PIII S PIII S PIII S MLFK	* YND GSEG GSEG I.A I.A DECP N KN G*.S I.P.Q YSTA S INT IANN VFDS TEVP 	T. P RLL WGH 	DEQ LLG	DY(DR: N* DGC S CGF S CGF S CGF S CGF S CGF S CGF S CGF S CGF S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGC S CGCC S CGCC S CGCC S CGCC S CGCC S CGCC S CGCC S CGCC S CGCC S CGCC S CGCC S CGCC S CGCC S CGCC S CGCC S CGCC S CGCC S CGCC S CGCC S CGCC S CGCC S CGCC S CGCC S CGCC S CGCC S CGCC S CGCC S CGCCCC S CGCC S CGCC S CGCCC S CGCCC S CGCCC S CGCCC S CGCCC S CGCCCCCC S CGCCCCCCCC	2IR IVIN FCITC	1AKS TRS Ω Ω Ω Ω Ω Ω Ω Ω.	SY TS *G N. *CA PAA 577 	KP(WH: YF YP: YT 2)	GR. S. 	GG KL Q. M. PA	*. QL.* YKL. ST I FK*	IQC GVI SVT. YPM STFF I THY F RDI VKI	IDI: TF IT* IPS(G.) IFY ICK(CG.) IFY ICK(CG.)	*S* SDF *NG SSI SSI SSI SSI SSI SSI SSI SSI SSI SS	VS:	STSI IRIN * T. SA.S TATI SVI * SVI * SVI * SVI * SUI *	GE	
NDV BPIV: HPIV: Senda SV5 NDV BPIV: Senda SV5 NDV BPIV: Senda SV5 NDV BPIV: Senda Sv5	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3		EGKY IPMR.S IPMR.S IFFSND P.NT LS *P NAFT SREN Q.I. A.L. IFQP 	V I Y K Q N Y W L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L L 	* YND GSEG 	T. P RLL WGH 	DEQ LLG MY SCP SCP SSRI S SSRI	DY(DR: N* STSI DGC KE GF NS CLA LA SQUI TR	LINI LINI LINI LINI R. KDV SSS	1AKS TRS ΩΩ ΩΩ ΩΩ ΩΩ ΩΩ ΩΩ ΩΩ ΩΩ ΩΩ ΩΩ ΩΩ ΩΩ ΩΩ ΩΩ ΩΩ ΩΩ ΩΩ ΩΩ ΩΩ ΩΩ ΩΩ ΩΩ ΩΩ ΩΩ ΩΩ ΩΩ ΩΩ ΩΩ ΩΩ ΩΩ ΩΩ ΩΩ ΩΩ ΩΩ ΩΩ ΩΩ ΩΩ ΩΩ ΩΩ ΩΩ ΩΩ ΩΩ ΩΩ ΩΩ ΩΩ ΩΩ ΩΩ Ω	SY TS *G N. *CA PAAG 5777 	KP(WH: 	GR. S. 	GG KL Q. M. PA	*. QL.*K YL. ST I.F K*	100 GVI * * * * YPM N STFF I THY F RDI VKI	IDI: TF IT* IPS: G. IFY: IFY: IFY: IS: G. IFY: IS: IFY: IS: IS: IS: IS: IS: IS: IS: IS: IS: IS	*S* SDFF *NG SSI SSI AAAT F	NNN SD HP K V S C K V S C C C C C C C C C C C C C C C C C C	STSI IRIN *T. SA.S TATI SVI *.T GSY RG*F FHIV 	GEI	
NDV BPIV: HPIV: Senda SV5 NDV BPIV: Senda SV5 NDV BPIV: BPIV: Senda SV5 NDV BPIV: Senda SV5 NDV	3 3 3 3 3 3 3 3 3 3 3 3 3 3		EGKY IPMR.S IPMR.S IFFSND P.NT LS PNAFT SREN I.V. Q.I. A.L. IFQP 	VIYK QNYW L .VLM VTLM RPGN S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S 	* YND GSEG 	T. P RLL 	DEQ LLG	DY(DR: N* TSI DGC KE GF SQQI TR	LINI LINI LINI LINI R. KDV SSS	14 K S T R S Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q	SY TS TS TS TS TS TS TS TS TS TS	KP(WH: YF YP YT YT 	GR. S PMT. L TT.S.S. H.T.	GG KL Q. PA PA	*. QL.* YL. ST I.F K*	IQC GVI **** YPM STFF I THY FF	24. 101: 177: 178: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 198: 1	*S* SDFF *NG SSI SSI SSI SSI SSI SSI SSI SSI SSI SS		STSI IRINA *T. SA.S TATI SVI *.T GSY RG *F FHIV 	GEI	
NDV BPIV: Senda SV5 NDV BPIV: HPIV: Senda SV5 NDV BPIV: HPIV: Senda SV5 NDV BPIV: HPIV: Senda SV5 NDV	3 3 3 3 3 3 3 3 3 3 3 3 3		EGKY IPMR.S .ITM FSND P.NT LS *P NAFT SREN. .V. 2.I. 	VIYK QNYW L .VLM VTLM RPGN T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T 	* YND GSEG GSEG A A DECP N K N K G * S TEVP VFDS TEVP S * N VFDS TEVP V S * N V S * N V S * N V S * N V S * N V S * N V S * N V S * N V S * N V S * N V S * N V S * N V S * N V N V S * N V N V N V N V S * N V N V N V N V N V N V N V N V S * N V S * N N V N V N V N V N V N V N V N V N N V N N V N N V N N V N N N V N N N V N N N V N N N N N N V N N N N N N N N N N N N N	T. P RLL 	DEQ LLG	DY(DR: N* TSI DGC KE GF S LA: S EAI	LYIN · Y · Y · Y · Y · Y · Y · Y · Y	14 KS 1 TRS 2 TRS 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	SY TS TS TS TO TO TO TO TO TO TO TO TO TO	KP(WH: 	GR. SPMT LTN TT.SS H.T.	GG KL Q. PA PA	*. QL.* YKL. ST I FK*	IQG GVI **** YPM STFF I THY FF	24. 101: 	*S* SDFY *NG GSI AAAT RAAT		STSI IRI SA.ST SA.TI SVI SVI SVI SVI SVI LS.F	GEI	
NDV BPIV: Senda SV5 NDV BPIV: Senda SV5 NDV BPIV: BPIV: Senda SV5 NDV BPIV: Senda SV5 NDV BPIV: Senda SV5 NDV	3 3 3 3 3 3 3 3 3 3 3 3 3		EGKY IPMR.S .IID P.NT LS *P NAFT SREN .V. 2.I. .L. 2.I. .L. 2.I. .L. .2. .I. 	VIYK QNYW VI VTLM VTLM VTLM VTLM VTLM VTLM S VI VP.II VPLI	* YND GSEG G I.A I.A DECP VSTA KN G*.S IIP.Q VYSTA S TEVP S*. RQ.T V.*L	T. P RLL WGH WGH 	DEQ LLC.KMY.SS.K.R.S.S. KR VSSI S.KAE GVR	DY(DR: N* TSI PDG(KE GF NS LA: SQQI TR' 	LYIN · Y · Y · Y · Y · Y · Y · Y · Y	Q.Q.Q.C. Q.C. Q.C. VY1 	SY TS: *G N. *G N. *C N. *C N. *C N. *C N. *C N. *C N. *C N. *C N. *C N. *C N. *C N. *C N. *C N. *C N. *C N. *C N. *C N. *C N. *C N. *C N. *C N. *C N. *C N. *C N. *C N. *C N. *C N. *C N. *C N. *C N. *C N. *C N. *C N. *C N. *C N. *C N. *C N. *C N. *C N. *C N. *C N. *C N. *C N. *C N. *C N. *C N. *C N. *C N. *C N. *C N. *C N. *C N. *C N. *C N. *C N. *C *C *C *C *C *C *C *C *C *C	KP(WH: YF YF YT 2) 2) 5) 7)	GR. S. PMT L. TTNS TTNS S. H. T	GG KL Q. PA PA	* · QL · · · YK · · · FK *	IQC GVI *** VT. YPM N. STF I THY F	24. 101: 17: 17: 17: 17: 17: 17: 17: 1	*S* SDFY *NG GSI AAAT RAAT		STSI IRINATI SVI SVI GGY FHIV LS.A	GE	DP NV L MN N SSN
NDV BPIV: Senda SV5 NDV BPIV: Senda SV5 NDV BPIV: BPIV: Senda SV5 NDV BPIV: Senda SV5 NDV	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3		EGKY IPMR SIT FSND P.NT LS P.NT SREN NAFT NAFT SREN L. L. L. L. 	VIYK QNYW VIYK PQNYW VTLM VTLM VTLM VTLM VTLM VTLM TSA MLFK VP.II VPLL ROTE	* YND GSEG GSEG A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A I.A.	T. P RLL WGH WGH WGH 	DEQ LLG	DY(DR: N* TSI PDG(KE GF NS LA: SQQI TR' SREAI	LYIY · Y · Y · Y · Y · Y · Y · Y ·	TRS TRS Q. Q. Q. C VY1 	SY TS: *G N. *G N. *C N. *C N. *C N. *C N. *C N. *C *C *C *C *C *C *C *C *C *C	KP(WH: 	GR. S. PMT L. TTNS TTNS STN H. T	GG KL Q. M. PA	* · · · · · · · · · · · · · · · · · · ·	IQC GVI *** VT. YPM N.SF I STFI THY F	A	*S* SDF *NG GSI. AAAT GSI. VVV T		STSI IRINATI SVI SVI SVI FHIV LS.F	GE	
NDV BPIV: Senda SV5 NDV BPIV: Senda SV5 NDV BPIV: Senda SV5 NDV BPIV: Senda SV5 NDV	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 8 PIV		EGKY IPMR SIT FSND P.NT FSND LS P.NT SREN NAFT SREN 2.I. IFQP 2I IFQP 2I IFQP 2I IFQP 	VIYK QNYW L .VLM VTLM VTLM RPGN T S PIIT .*S PIIT .*S MLFK VPLI VPLL ROTE	* YND GGSEG GGSEG LA LA DECCP NN GG*.S GF.S GF.S GF.S TEVP VYSTA STEVP VYSTA S*. RQ.T VV-S L IN	T. P RLL WGH 	DEQ LLG	DY(DR N* SS TSI DGC KE GF NS CUI	LYIN · Y · Y · Y · Y · Y · Y · Y · Y	IAKS TRS Q. Q. Q. SVY1	SY STS STS STS STS STS STS STS S	KP(WH: 	GR. S. PMT L. TTNS S. H. T	GG KL Q. M. PA PA	*. QL. YKL. ST I. FK* 89	I Q Q G V I Y P M S S T F I T H Y S S T F I T H Y V K T	A	*S* SDF *NG GSI.AANT GSI.AANT GSI.AANT		STSI IRINA * SA.SS TATI SVI * .T GSY FHIV. LS.A	GEI	
NDV BPIV: Senda SV5 NDV BPIV: SV5 NDV BPIV: Senda SV5 NDV BPIV: Senda SV5 NDV BPIV: Senda SV5 NDV	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 4 1 4 1		EGKY IPMR SIT FSND P.NT LS P.NAFT SREN NAFT SREN 2.I. 2.I. IFQP 2.I. IFQP 2 I I SREN NAFT SREN NAFT SREN NAFT SREN NAFT SREN NAFT SREN NAFT SREN NAFT SREN NAFT SREN NAFT SREN NAFT SREN NAFT SREN NAFT SREN NAFT SREN NAFT SREN NAFT SREN NAFT SREN NAFT SREN NAFT SREN NAFT SREN NAFT SREN NAFT SREN NAFT SREN NAFT SREN NAFT SREN NAFT SREN NAFT SREN NAFT SREN NAFT SREN NAFT SREN NAFT SREN SREN SREN SREN SREN SREN SREN SREN	VIYK VIYK VIYK VIYK VIYK VIYK VIYK RPGN VI VI VI VI VI VI VI VI VI VI	* YND GGSEG GGSEG 	T. P RLL WGH WGH WGH RLL WGH 	DEQ LLLG	DY(DR N* SS TSI DGC KE GF NS CUI SCUI	UIRN UIRN UIRN UIRN UIRN UIRN UIRN UIRN	IAKS TRS Q. Q. Q. SVY1	SY 57 TS - G - CA - C	KP(WH: 	GR. S. PMT L. TNS S. H. TNS S. H. T	GG KL. Q. MPA PA PS C. F F	* · QL · · · · · · · · · · · · · · · · ·	IQC GVI VT- VT- VT- STFFI THY STFFI THY STFFI VKT	A. IDI: TF IT* IPS(ARG		STSI IRINA STSI STATI SVI SVI SVI SVI SVI SVI SVI SVI SVI SV	GEI	
NDV BPIV: Senda SV5 NDV BPIV: BPIV: Senda SV5 NDV BPIV: Senda SV5 NDV BPIV: Senda SV5 NDV I I I I I I I I I I I I I I I I I I I	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3		EGKY IPMR SSIT FSND P.NT LS P.NT SREN NAFT SREN 2.I. 2.I. 2.I. 2.I. 2 E.RI HN P 2.80 2.45	VIYK VIYK QNYW VIYK VIYK VIYK VIYK RPGN PIIT T.MY VP.II VPLI ROTE 	* YND GSEG GSEG LA DECP NN G*.S LIP.Q YSTA SV.T VFDS TEVP V.TL VFDS TEVP SQ.T V.V.*L LIN MA SLN GLN	T. P RLL RLL WGH WGH NATN AATN AATN AATN AATN 	DEQ LLG	20Y(10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R: 10R:	ITTO	IAKS TRS Q.	SY 57. • G 1. • G 1.	K P (W H: ···· Y F ···· Y F ···· Y F ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ···· ····· ····· ····· ····· ····· ····· ····· ····· ····· ······	GR. S. TT. T. TN.S.S.TT. GR. T. T. T	GG KL. Q. MPA PA PS C	* · QL·* YL· ST I··F* 8 732	IQQ GVI VYPM N.SS TFI STFI THY FT RDT	A. IDI: TF' IT' IT' IFS' IFY' IFY' IGS' ISS' ISS'	ACT STAND	= 2 = 3	STSI IRIN SASS SASS SVI SVI SVI SVI SVI SVI SVI SVI SSY RG FF	GEI	
NDV BPIV: SV5 NDV BPIV: SV5 NDV BPIV: SV5 NDV BPIV: SV5 NDV BPIV: SV5 NDV I I I I I I I I I I I I I I I I I I I	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3		EGKY IPMR SIT FSND P.NT SREN NAFT SREN V.2.I. V.2.I. FFQP FFQP E.RI HN P 2.80 2.45 2.45 2.45	VIYK VIYK VIYK VIW VTLM RPGN FIIT TSA MLFK VPLL ROTE	* YND GSEG GSEG LA LA DDECP VSTA KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN KN K	T. P RLL WGH WGH NATN AASA TNR 	DEQ LL.S.Y.Y.S.S.K.Y.S.S. * SSR S.K.AE GVR 0 LE 83 10	DY(DY(DR: N* TSI PDG(CCU 	QIRN IYIY + Y HF CITC CITC - + - - + - + - + - - + - - + - - - - -	IAKS TRS Q.	SY 57. • G 1. • G 1.	KP4 WH: W YF YP W YF W YT 2) 2) 5) 5) 7) T = 3 = 1 = 4	G S	GG KL. Q. M. PA PS C	* Q*YL ST IF* 8 7322	I Q Q G V I I I I I I I I I I I I I I I I I I	2A. (DI) 	A GLYS	= 2 = 3 = 2	8 2 4 4	GE WT 	DP NV L M. HQSSN 0908
NDV BPIV: Senda Sv5 NDV BPIV: Senda Sv5 NDV BPIV: Senda Sv5 NDV BPIV: Senda Sv5 NDV BPIV: Senda Sv5 NDV	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3		EGKY IPMR SS FSND P.NT LS *P NAFT SREN. V. J.V. J.V. J.V. J.V. J.V. J.V. J.V.	VIYK VIYK VIYK VIW RPGN VIW RPGN VIW RPGN VIW S S S S S S S S S S S S S S S S S S S	* YND GS EG GS EG 	T. P. R.LL. R.LL. 	DEQ LLC	DY(DR: N* TSI DGC KE GF CQQI TR S REAI	QIRN IYIY HF* CITC CITC CITC CITC CITC CITC CITC CIT	IAKS TRS Q.	SY ST. G. ST. C. ST. C. S.	KP4 WH: W YF YP W YT YT 2) 2) 5) 5) 7) T = 3 = 1 = 4 = 2	G S	GG KL QM PS	* QYL ST IF* 8 73222	I Q Q G V I Y Y P N S T I Y F I Y F I Y S T I Y S T I Y F	2A. (DI) 	AS A STANDARD SAAATH AGUSE	= 2 = 2 = 2 = 4	8 2 4 9 8	GE AQ H* GT 	DP

Fig. 5. Comparison of the deduced amino acid sequence of the HN protein of BPIV3 with those of HPIV3, Sendai virus, SV5 and NDV, and deduced amino acid composition of BPIV3 HN protein. See the legend for Fig. 4.



Fig. 6. Schematic illustration of the BPIV3 genome RNA. The region having been elucidated to date is written in solid line. Numbers in [] and () denote nucleotide numbers in non-coding regions and amino acid numbrers of the gene products, respectively. It was determined that in the L gene a large reading frame opened after the 3' proximal non-coding region consisting of 12 nucleotides excluding R1 (data not shown). Le; leader region, R1 and R2; repeating consensus sequences, and I; intergenic trinucleotide (GAA).

thought to act both as an anchor in the viral envelope and as a signal peptide for membrane translocation (6, 16, 17, 19, 21, 22). Furthermore, 9 Cys, 12 Gly, 6 Pro and 6 Tyr residues were aligned in corresponding positions. Moreover, 9 corresponding positions were occupied by basic residues, Arg or Lys, and 12 by Ser or Thr. In addition, as marked by dashed underlines in Fig. 5, seven small regions were fairly well conserved in these five viruses, and were therefore thought to have roles in the hemagglutinating and neuraminidase activities.

On the other hand, no Asn-linked carbohydrate attachment signal was conserved in the viruses. All three presumed carbohydrate attachment sites (Asn-Pro-Thr or Ser was excluded, and the signal sequence in the region which seemed to be on the inside of the viral envelope was neglected) of HPIV3 were shared by BPIV3, but the latter had two additional sites, one of which was shared by Sendai virus.

It is very interesting to note that the H protein of measles virus (24) showed only chance homologies (less than 10%) with the HN proteins of these viruses.

DISCUSSION

In the present study, we determined the genome structure of the F and HN gene regions of BPIV3 910N strain by analysis of cDNA copies constructed from genomic RNA. Thus, together with the results in our preceding paper, the genome has been elucidated, without gaps, from its 3' end to the terminal point of the HN gene, covering 8,638 nucleotides. This region is schematically illustrated in Fig. 6. The corresponding region of HPIV3, apart from the M gene, has already been determined (18, 19, 35, 36, 37, 38, 39).

The F and HN genes of BPIV3 share the universal feature of genes of paramyxoviruses in that they are flanked at the 3' end by the starting consensus sequence, here named R1, and at the 5' end by the terminating consensus sequence, R2, which is regarded as the signal for polyadenylation. A characteristic feature common to BPIV3 and HPIV3 (18) is that the 3' non-coding region of the F gene, from the R1 to the opening of the coding frame, is extremely long and U-rich, though it is more marked in BPIV3. This could cause the viral RNA polymerase to incorrectly recognize the polyadenylation signal of the M gene, as described in the preceding paper.

The high F and HN amino acid homologies of about 80% observed between BPIV3 and HPIV3 indicate that the viruses are closely related. However, the homologies are not as high as those observed between virus strains of Sendai virus, which are more than 95 % (6). Furthermore, differences in the presumed carbohydrate attachment sites and the nucleotide sequences of non-coding regions of these genes indicate that they are not substrains of the same virus. These findings are consistent with the previous findings of Abinanti et al. (10) that guinea pig antisera against BPIV3 and HPIV3 showed much higher neutralization and hemagglutination inhibition titers aginst the homologous than against the heterologous virus, and also that in similar tests sera from HPIV3-infected children exhibited much higher titers against HPIV3. In this context, alteration of glycoprotein carbohydrate attachment sites may be important in antigenic differentiation between BPIV3 and HPIV3, as suggested by Skehel et al. for influenza virus (40) and Vandepol et al. for vesicular stomatitis virus (41).

In comparison of amino acid sequences of the F and HN proteins, the BPIV3-HPIV3 group showed considerably higher homologies with Sendai virus than with SV5 and NDV. As presented in the preceding paper, the NP and M proteins, both of which constitute the basic structure of virion, show most conservation between BPIV3 and Sendai virus, while the P and C proteins, which seem to be functionally important within infected cells, are not so well conserved. The degree of conservation of the F and HN glycoproteins, which mediate attachment and penetration of virus into the cells, is lower than that of the NP and M proteins, but higher than that of the P and C proteins, suggesting that the evolutionary shifts between viruses vary from one group of proteins to another. This tendency is also detectable even between BPIV3 and HPIV3.

On the other hand, although the amino acid homology varies greatly depending on the combinations of BPIV3, HPIV3, Sendai virus, SV5 and NDV, the F as well as HN proteins show basic structures common to all these viruses. The distribution of important hydrophobic domains in F protein (signal peptide, amino terminal of F1 subunit and anchoring region) is very similar in all viruses. Moreover, 10 Cys, 7 Gly and 4 Pro residues, which seem to be important in determination of protein structure, are conserved at corresponding positions. Four well-conserved short sequences (dashed underlines in Fig. 4) could have some role either in maintaining the F protein structure or in membrane fusion in concert with the amino terminal hydrophobic domain of the F1 subunit.

As for the HN proteins of these viruses, they all have their most hydrophobic domain near the amino terminal, which is thought to act as both signal peptide and anchor. Here again, 9 Cys, 12 Gly and 6 Pro residues are conserved at the same corresponding positions. Moreover, 9 basic residues (Arg or Lys), 12 hydroxy residues (Ser or Thr) and 6 Tyr residues are also conserved at corresponding positions, although their significance remains unclear. Furthermore, seven short regions (dashed underlines in Fig. 5) are locally well conserved in the HN proteins of these viruses, and are thought to act as functional domains in hemagglutination and hydrolysis of sialic acids. It is surprising that the H protein of measles (24) virus shows only chance homologies with any of the HN proteins of BPIV3, HPIV3, Sendai virus, SV5 and NDV. This may be a reflection of the fact that measles virus lacks neuraminidase activity and agglutinates red blood cells from only a limited number of animal species, in sharp contrast to parainfluenza viruses.

Thus, accumulating information is delineating the common basic structures as well as the evolutionary changes of the paramyxovirus glycoproteins, and it now seems essential to compare the genes of virus mutants carrying defects in activities mediated by the glycoproeins, in order to obtain more insight into functional domain structures.

During preparation of this manuscript, an amino acid sequence corresponding to the region between the 65th and 549th residue of the HN protein of the BPIV3 910N strain was reported for BPIV3 SF-4 strain (42). The main bulk of the sequence was virtually identical in the two strains, but the last region from the 523rd to 549th residue was completely different. Our own analysis demonstrated that there was no such difference between the 910N, SC and M strains of BPIV3 (data not shown).

ACKNOWLEDGEMENT

This work was supported by grants from the Ministry of Education, Science and Culture and the Ministry of Health and Welfare of Japan.

*To whom correspondence should be addressed

REFERENCES

- 1. Hsu,M-C., Scheid,A. and Choppin,P.W. (1979) Virology 95, 476-491.
- Merz,D.C.,Scheid,A. and Choppin,P.W. (1980) J.Exp.Med. 151, 275-288.
- Long,L., Portetelle,D., Ghysdael,J., Gonze,M., Burny,A. and Meulemans,G. (1986) J.Virol. 57, 1198-1202.
- 4. Ray, R. and Compans, R.W. (1986) Virology 148, 232-236.
- Rydbeck, R., Oervell, C., Loeve, A. and Norrby, E. (1986) J.gen.Virol. 67, 1531-1542.
- Shioda, T., Iwasaki, K. and Shibuta, H. (1986) Nucleic Acids Res. 14, 1545-1563.
- 7. Drzeniek, R., Boegel, K. and Rott, R. (1967) Virology 31, 725-727.
- Shibuta, H., Kanda, T., Hazama, A., Adachi, A. and Matumoto, M. (1981) Infect.Immun. 34, 262-267.
- Shibuta,H., Nozawa,A., Shioda,T. and Kanda,T. (1983) Infect.Immun. 41, 780-788.
- Abinanti,F.R., Chanock,R.M., Cook,M.K., Wong,D. and Warfield,M. (1961) P.S.E.B.M. 106, 466-469.
- 11. Fischman, H.R. and Bang, F.B. (1966) P.S.E.B.M. 121, 966-970.
- 12. Scheid, A. and Choppin, P.W. (1977) Virology 80, 54-66.
- 13. Shibuta, H., Suzu, S. and Shioda, T. (1986) Virology 155, in press.
- Blumberg, B.M., Giorgi, C., Rose, K. and Kolakofsky, D. (1985) J.gen.Virol. 66, 317-331.
- 15. Hsu,M-C. and Choppin,P.W. (1984) Proc.Natl.Acad.Sci.USA. 81, 7732-7736.
- Blumberg, B.M., Giorgi, C., Roux, L., Raju, R., Dowling, P., Chollet, A. and Kolakofsky, D. (1985) Cell 41, 269-278.
- Miura, N., Nakatani, Y., Ishiura, M., Uchida, T. and Okada, Y. (1985) FEBS lett. 188, 112-116.
- Spriggs, M.K., Olmsted, R.A., Venkatesan, S., Coligan, J.E. and Collins, P.L. (1986) Virology 152, 241-251.
- Elango, N., Coligan, J.E., Jambou, R.C and Venkatesan, S. (1986) J.Virol. 57, 481-489.
- 20. Hiebert, S.W., Paterson, R.G. and Lamb, R.A. (1985) J.Virol. 54, 1-6.
- Paterson,R.G., Harris,T.J.R. and Lamb,R.A. (1984) Proc.Natl.Acad.Sci. USA. 81, 6706-6710.
- 22. Millar, N.S., Chambers, P. and Emmerson, P.T. (1986) J.gen.Virol. 67, 1917-1927.
- 23. McGinnes,L.W. and Morrison,T.G. (1986) Virus Res. 5, 343-356.
- 24. Alkhatib, G. and Briedis, D. (1986) Virology 150, 479-490.
- 25. Okayama, H. and Berg, P. (1982) Mol.Cell.Biol. 2, 161-170.
- 26. Okayama, H. and Berg, P. (1983) Mol.Cell.Biol. 3, 280-289.

- 27. Sanger, F., Nicklen, S. and Coulson, A.R. (1977) Proc.Natl.Acad.Sci.USA. 74, 5463-5467.
- 28. Messing, J. (1983) Methods Enzymol. 101, 20-78.
- 29. Maxam, A.M. and Gilbert, W. (1980) Methods Enzymol. 65, 499-560.
- 30. Wong,T.C. and Hirano,A. (1986) J.Virol. 57, 343-348.
- Shibuta, H., Kanda, T., Nozawa, A., Sato, S. and Kumanishi, T. (1985) Arch.Virol. 83, 43-52.
- Gething, M.J., White, J.M. and Waterfield, M.D. (1978) Proc.Natl.Acad. Sci.USA. 75, 2737-2740.
- Richardson, C.D., Scheid, A. and Choppin, P.W. (1980) Virology 105, 205-222.
- 34. Chou, P.Y. and Fasman, G.D. (1974) Biochemistry 13, 211-222.
- 35. Dimock,K., Rud,E.W. and Kang,Y. (1986) Nucleic Acids Res. 14, 4694.
- 36. Galinski,M.S., Mink,M.A., Lambert,D.M., Wechsler,S.L. and Pons,M.W. (1986) Virology 149, 139-151.
- Sánchez, Á., Banerjee, A.K., Furuichi, Y. and Richardson, M.A. (1986) Virology 152, 171-180.
- 38. Luk, D., Sánchez, Á. and Banerjee, A.K. (1986) Virology 153, 318-325.
- 39. Spriggs,M.K. and Collins,P.L. (1986) J.Virol. 59, 646-654.
- 40. Skehel,J,J., Stevens,D.J., Daniels,R.S., Douglas,A.R., Knossow,M., Wilson,I.A. and Wiley,D.C. (1984) Proc.Natl.Acad.Sci.USA. 81, 1779-1783.
- 41. Vandepol,S.B., Lefrancois,L. and Holland,J.J. (1986) Virology 148, 312-325.
- 42. Coelingh,K.J., Winter,C.C., Murphy,B.R., Rice,J.M., Kimball,P.C., Olmsted,R.A. and Collins,P.L. (1986) J.Virol. 60, 90-96.